| Reference: | FOI.10190.22 |
|------------------|------------------|
| Subject: | Formularies |
| Date of Request: | 03 November 2022 |

Requested:

- 1. The process(es) for drugs which have a NICE Technology Appraisal?
- 2. The name of the formulary committee(s) that will be reviewing this on behalf of your organisation?
- 3. The forthcoming dates of these committee(s) meetings as far as they have been scheduled?
- 4. Name of the committee(s) Secretary and contact details?
- 5. Name of the committee(s) Chair and contact details?
- 6. Copies of the previous two minutes from the committee(s) meetings?
- 7. Copy of the Terms of Reference for the committee(s)?
- 8. Copy of the application form which needs to be completed, where a different form is applicable for different committees, please send over each one?

Response:

- Medications with a National Institute for Health and Care Excellence (NICE) Technology
 Appraisal and All Wales Medicines Strategy Group (AWMSG) approval are automatically
 added to Hywel Dda University Health Board's (UHB) formulary. Specific pathways for
 conditions are reviewed individually and the drugs are added to the pathway if approved.
- 2. The UHB's Medicines Management Operational Group (MMOG) reviews the UHB's formularies.
- 3. The final meeting for 2022 is scheduled for 29 November 2022. Meeting dates for the 2023 calendar year have yet to be confirmed.
- 4. The secretary of the UHB's MMOG group is:

Susan E Beach BPharm, MSc, MRPharmS Lead Clinical Development Pharmacist E-mail: sue.beach@wales.nhs.uk

5. The Chair of the UHB's MMOG is:

Dr Subhamay Ghosh Associate Medical Director For Quality & Safety

E-mail: Subhamay.Ghosh@wales.nhs.uk

- 6. The UHB has provided copies of the redacted minutes for the last two MMOG meetings at Attachments 1 and 2.
- 7. The UHB has provided a copy of MMOG's Terms of Reference at Attachment 3.
- 8. A copy of the UHB's internal application form is provided at Attachment 4. The application form is for completion by the Consultant who wishes to apply for a medicine to be added to the formulary by the Lead Clinical Development Pharmacist.